All Articles

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

Triple Flag's US$440M gold stream on Australia's Ravenswood mine is more than a deal. It's a look into the future of mining finance and strategic investment.

With new all-in-one systems, Growatt isn't just selling hardware. It's making a strategic bet on simplifying the energy transition for Europe's homes and businesses.

A landmark acquisition is set to 4x IQSTEL's net income. But the real story is its pivot from a low-margin carrier to a high-margin digital services powerhouse.

Kiplin Metals pairs advanced geophysics with a new investor strategy, aiming to unlock uranium riches in Saskatchewan's famed Athabasca Basin.

A new platform aims to help scam victims reclaim billions. But in the murky world of asset recovery, separating real help from false hope is a critical task.

KKR's accelerated capital returns and a major reporting overhaul reveal a recovering private equity landscape, a crucial sign for tech firms awaiting exits.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Engineering giant AtkinsRéalis secures a £340M role in a landmark UK government framework, positioning it at the heart of national security and renewal.

Adobe's new enterprise offering isn't just another AI tool; it's a strategic play to solve brand consistency and IP risks at scale. Is it the key to unlocking AI's true potential?

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

Convr's move to connect its risk engine to AI assistants via an open protocol isn't just a feature update; it's a blueprint for the future of underwriting.

BMO's new ZMPI fund isn't just another ETF. It's a bet on a hybrid strategy blending passive efficiency with systematic analysis. But can it deliver?

After decades of a fragmented identity, Del Monte consolidates its brand, aiming for growth by bridging the gap between fresh produce and center-aisle goods.

Americans feel more secure about retirement than ever, yet a new BlackRock study warns their savings may only cover half their needs, fueling a push for AI and 'personal pensions'.

An industrial giant is using youth football not just for charity, but as a core strategy to foster global collaboration, one friendship at a time.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.